首页|异基因造血干细胞移植后CMV和EBV共激活患者的临床研究

异基因造血干细胞移植后CMV和EBV共激活患者的临床研究

扫码查看
目的:探讨异基因造血干细胞移植(allo-HSCT)后巨细胞病毒(CMV)和EB病毒(EBV)共激活患者的临床特点、危险因素及其对预后的影响.方法:收集2015年1月至2020年12月接受allo-HSCT的222例患者临床资料,根据是否发生CMV、EBV感染进行分组,采用Kaplan-Meier法进行生存分析,Cox比例风险回归模型分析CMV、EBV共激活的危险因素.结果:allo-HSCT后发生CMV和EBV共激活患者(CMV++EBV+组,即CMV及EBV合并感染)30例,CMV血症患者(CMV+组)101例,EBV血症患者(EBV+组)149例,CMV、EBV未激活患者(CMV-+EBV-组)28例.与其他组相比,CMV++EBV+组中急性移植物抗宿主病、出血性膀胱炎发生率更高(53.3%vs 42.6%、36.9%、17.9%,P<0.001;36.7%vs 32.7%、22.8%、10.7%,P=0.042).CMV++EBV+组与 CMV+组、EBV+组移植后淋巴细胞增殖性疾病患者的发生率类似(3.3%vs3.0%、3.4%,P=0.811).单因素及多因素分析结果显示,移植后CMV+持续时间、EBV+持续时间是CMV和EBV共激活患者的独立危险因素.与其他组相比,CMV++EBV+组患者 2 年总生存率、2 年无病生存率较低(46.7%vs 74.9%、83.4%、71.4%,P<0.001;46.7%vs 70.9%、79.5%、69.9%,P=0.002),2 年非复发死亡率较高(48.2% vs 22%、13.6%、18.7%,P<0.001).结论:移植后CMV+持续时间、EBV+持续时间是CMV和EBV共激活患者的独立危险因素.CMV和EBV共激活患者的总生存率、无病生存率更低,非复发死亡率更高,临床预后更差.
Clinical Study of Allogeneic Hematopoietic Stem Cell Transplanta-tion Patients with Co-Reactivation of Cytomegalovirus and Epstein-Barr Virus
Objective:To explore the clinical characteristics and risk factors of cytomegalovirus(CMV)and Epstein-Barr virus(EBV)co-reactivation after allogeneic hematopoietic stem cell transplantation(allo-HSCT)and its influence on prognosis.Methods:The clinical data of 222 patients who received allo-HSCT from January 2015 to December 2020 were collected,and the patients were divided into groups according to the occurrence of CMV and EBV infection.Kaplan-Meier method was used for survival analysis,and Cox proportional hazard regression model was used to analyze the risk factors of co-reactivation of CMV and EBV.Results:After allo-HSCT,there were 30 patients with co-reactivation of CMV and EBV(CMV++EBV+group),101 patients with CMV viremia(CMV+group),149 patients with EBV viremia(EBV+group),and 28 patients with CMV and EBV inactivation(CMV-+EBV-group).Compared with the other groups,the incidence of acute graft-versus-host disease(aGVHD)and hemorrhagic cystitis(HC)was higher in CMV++EBV+groups(53.3%vs 42.6%,36.9%,17.9%,P<0.001;36.7%vs 32.7%,22.8%,10.7%,P=0.042).The incidence of post-transplant lymphoproliferative disease(PTLD)in CMV++EBV+group was similar to CMV+group and EBV+group(3.3%vs 3.0%,3.4%,P=0.811).Univariate and multivariate analysis showed that the persistent time of CMV and EBV after transplantation were independent risk factors for co-reactivation of CMV and EBV.Compared with the other groups,the 2-year overall survival(OS)rate and 2-year disease-free survival(DFS)rate of patients inCMV++EBV+group were lower(46.7%vs 74.9%,83.4%,71.4%,P<0.001;46.7%vs 70.9%,79.5%,69.9%,P=0.002),and 2-year non-recurrence mortality(NRM)was higher(48.2%vs 22%,13.6%,18.7%,P<0.001).Conclusion:The persistent time of CMV and EBV after transplantation are independent risk factors for patients with co-reactivation of CMV and EBV.Patients with co-reactivation of CMV and EBV had lower OS and DFS rate and higher NRM,suggesting that the clinical prognosis of the patients are worse.

allogeneic hematopoietic stem cell transplantationcytomegalovirusEpstein-Barr virusco-reactivationprognosis

王之玮、刘琼、孙海英

展开 >

徐州医科大学附属医院血液科,江苏徐州 221000

异基因造血干细胞移植 巨细胞病毒 EB病毒 共同激活 预后

2024

中国实验血液学杂志
中国病理生理学会

中国实验血液学杂志

CSTPCD北大核心
影响因子:0.988
ISSN:1009-2137
年,卷(期):2024.32(2)
  • 20